Heparin Dosage Calculator
Calculate precise heparin dosing for therapeutic anticoagulation with our interactive tool. Includes bolus and infusion calculations with visual dose-response analysis.
Heparin Dosage Results
Bolus Dose:
–
Initial Infusion Rate:
–
Maintenance Dose:
–
aPTT Monitoring:
–
Special Considerations:
–
Comprehensive Guide to Heparin Dosage Calculations
Heparin remains one of the most commonly used anticoagulants in clinical practice, requiring precise dosage calculations to balance therapeutic efficacy with bleeding risk. This guide provides healthcare professionals with evidence-based protocols for heparin administration across various clinical scenarios.
Understanding Heparin Pharmacology
Heparin exerts its anticoagulant effect by:
- Activating antithrombin III, which inactivates thrombin (factor IIa) and factor Xa
- Preventing the conversion of fibrinogen to fibrin
- Inhibiting platelet aggregation
Key pharmacokinetic properties:
- Rapid onset of action (immediate when IV, 20-60 minutes when SC)
- Short half-life (1-2 hours for UFH, 3-6 hours for LMWH)
- Primarily metabolized in the liver (UFH) or excreted renally (LMWH)
- Does not cross the placenta (safe in pregnancy)
Clinical Indications for Heparin Therapy
| Indication | Typical Duration | Target aPTT Range | Common Heparin Type |
|---|---|---|---|
| Venous Thromboembolism (VTE) Treatment | 5-10 days | 1.5-2.5× baseline | UFH or LMWH |
| VTE Prophylaxis (post-op) | 7-14 days | Not typically monitored | LMWH preferred |
| Acute Coronary Syndrome | 48-72 hours | 1.5-2.0× baseline | UFH |
| Atrial Fibrillation with Hemodynamic Instability | Until stable | 1.5-2.5× baseline | UFH |
| Pregnancy-Related VTE | Throughout pregnancy | Anti-Xa monitoring | LMWH |
Unfractionated Heparin (UFH) Dosing Protocols
Standard UFH dosing follows a weight-based protocol with the following components:
- Bolus Dose: 80 units/kg (or 5,000 units for average adults)
- Initial Infusion: 18 units/kg/hour
- Maintenance: Adjust based on aPTT results (typically every 6 hours until stable)
aPTT Monitoring Protocol:
- Check aPTT 6 hours after initiation
- Adjust infusion rate based on nomogram:
| aPTT Result | Bolus Dose | Infusion Rate Change | Next aPTT Check |
|---|---|---|---|
| <35 sec (<1.2× baseline) | 80 units/kg | Increase by 4 units/kg/hour | 6 hours |
| 35-45 sec (1.2-1.5× baseline) | 40 units/kg | Increase by 2 units/kg/hour | 6 hours |
| 46-70 sec (1.5-2.3× baseline) | No bolus | No change | Next AM |
| 71-90 sec (2.3-3.0× baseline) | No bolus | Decrease by 2 units/kg/hour | 6 hours |
| >90 sec (>3.0× baseline) | Hold infusion 1 hour | Decrease by 3 units/kg/hour | 6 hours |
Low Molecular Weight Heparin (LMWH) Dosing
LMWH offers several advantages over UFH:
- More predictable anticoagulant response
- Longer half-life allowing once or twice daily dosing
- Lower risk of heparin-induced thrombocytopenia (HIT)
- No routine monitoring required in most patients
Common LMWH Dosing Regimens:
- Enoxaparin (Lovenox):
- VTE Treatment: 1 mg/kg SC every 12 hours or 1.5 mg/kg SC daily
- VTE Prophylaxis: 40 mg SC daily (30 mg SC every 12 hours for high-risk patients)
- ACS: 1 mg/kg SC every 12 hours with aspirin
- Dalteparin (Fragmin):
- VTE Treatment: 100 IU/kg SC every 12 hours or 200 IU/kg SC daily
- VTE Prophylaxis: 5,000 IU SC daily
Special Considerations for LMWH:
- Renal impairment requires dose adjustment (typically 50% reduction for CrCl < 30 mL/min)
- Obese patients: Use actual body weight (no cap) unless BMI > 40
- Pregnancy: Preferred over UFH due to lower risk of osteoporosis
- Anti-Xa monitoring recommended for:
- Pregnant women
- Patients with renal impairment
- Obese patients (BMI > 40)
- Pediatric patients
Heparin in Special Populations
Pediatric Patients:
- UFH initial bolus: 75-100 units/kg
- Infusion: 20-30 units/kg/hour
- Target aPTT range: 60-85 seconds (1.5-2.5× baseline)
- LMWH dosing: 1 mg/kg/dose SC every 12 hours (enoxaparin)
Obese Patients:
- Use actual body weight for dosing (no maximum cap)
- Monitor aPTT or anti-Xa levels closely
- Consider continuous infusion over intermittent boluses
Patients with Renal Impairment:
- LMWH accumulation risk with CrCl < 30 mL/min
- Consider 50% dose reduction or switch to UFH
- Monitor anti-Xa levels if using LMWH (target 0.5-1.0 IU/mL)
Pregnant Patients:
- LMWH preferred over UFH for long-term use
- Dose adjustments may be needed as pregnancy progresses
- Monitor anti-Xa levels monthly (target 0.6-1.0 IU/mL)
- Discontinue 24 hours before planned delivery (12 hours for UFH)
Monitoring Heparin Therapy
Unfractionated Heparin:
- Primary monitoring: aPTT (target 1.5-2.5× baseline)
- Alternative: Anti-Xa assay (target 0.3-0.7 IU/mL)
- Platelet count monitoring for HIT (baseline, then every 2-3 days)
- Monitor for bleeding (Hgb/Hct if clinically indicated)
Low Molecular Weight Heparin:
- Routine monitoring not required for most patients
- Anti-Xa monitoring recommended for:
- Pregnant women
- Renal impairment (CrCl < 30 mL/min)
- Obese patients (BMI > 40)
- Pediatric patients
- Target anti-Xa range: 0.5-1.0 IU/mL (4 hours post-dose for twice-daily dosing)
Complications of Heparin Therapy
Heparin-Induced Thrombocytopenia (HIT):
- Type I: Mild, transient thrombocytopenia (platelets > 100,000/μL)
- Type II: Immune-mediated (platelets < 100,000/μL or >50% drop)
- Paradoxical thrombosis risk with Type II HIT
- Management: Discontinue heparin, start alternative anticoagulant (argatroban, bivalirudin)
Bleeding Complications:
- Major bleeding occurs in 1-5% of patients
- Risk factors: Advanced age, renal impairment, concomitant antiplatelet therapy
- Management:
- Mild bleeding: Reduce dose or temporarily hold
- Severe bleeding: Discontinue heparin, consider protamine sulfate
Osteoporosis:
- Risk increases with prolonged UFH use (>1 month)
- LMWH has lower risk of osteoporosis
- Consider calcium/vitamin D supplementation for long-term therapy
Transitioning from Heparin to Warfarin
Proper overlap is crucial to prevent warfarin-induced skin necrosis:
- Start warfarin on day 1 of heparin therapy
- Continue heparin for minimum 5 days AND until INR ≥ 2.0 for 24 hours
- Typical overlap duration: 4-7 days
- Monitor INR daily during transition
Important Considerations:
- Warfarin increases protein C levels before other vitamin K-dependent factors, creating temporary hypercoagulable state
- Heparin should not be discontinued until INR is therapeutic
- For patients with mechanical heart valves, target INR may be higher (2.5-3.5)
Reversal of Heparin
Protamine Sulfate Dosing:
- 1 mg protamine neutralizes 100 units UFH (given over 1-3 minutes)
- Maximum single dose: 50 mg
- For LMWH: 1 mg protamine per 1 mg enoxaparin (or 100 IU dalteparin)
- Second dose may be given if bleeding continues (0.5 mg per 100 units UFH)
Monitoring After Reversal:
- Check aPTT 5-15 minutes after administration
- Monitor for rebound anticoagulation (may occur 2-4 hours later)
- Watch for adverse reactions (hypotension, bradycardia, anaphylaxis)
Alternative Anticoagulants
When heparin is contraindicated or ineffective:
- Argatroban: Direct thrombin inhibitor (dosing: 2 mcg/kg/min, adjust based on aPTT)
- Bivalirudin: Direct thrombin inhibitor (dosing: 0.15-0.20 mg/kg/hour)
- Fondaparinux: Synthetic pentasaccharide (dosing: 2.5 mg SC daily for VTE prophylaxis, 5-10 mg daily for treatment)
- Direct Oral Anticoagulants (DOACs):
- Apixaban, rivaroxaban, dabigatran, edoxaban
- No routine monitoring required
- Contraindicated in severe renal/hepatic impairment
Clinical Pearls for Heparin Management
- Always verify patient weight (use most recent accurate measurement)
- Document baseline aPTT, platelet count, and renal function
- For continuous infusions, use electronic infusion pumps for precision
- Educate patients on signs of bleeding and HIT (bruising, petechiae, new thrombosis)
- Consider pharmacist consultation for complex cases (renal impairment, obesity, pregnancy)
- For surgical patients, time last dose to allow for adequate hemostasis
- Monitor for drug interactions (especially with other anticoagulants or antiplatelets)